Evidence Base
The Value of Earlier Initiation of Anti-Amyloid Therapy for Alzheimer’s Disease
December 4, 2025
Featured Experts: Jack M. Chapel, PhD
Research
All Research Featured Research
Perspective
Assessing the Case Against Direct-to-Consumer Drug Advertisements
November 14, 2025
Featured Experts: Neeraj Sood, PhD
Perspective
Federally Fueled Hospital Drug Sales Must Be Reformed
November 14, 2025
Featured Experts: Ryan Long, Karen Mulligan, PhD
News
White House Move to Expand Obesity Drug Access Informed by Schaeffer Research
November 10, 2025
Comment Letter
Response to the Draft Report of the Health Economics Methods Advisory (HEMA): “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies”
October 21, 2025
Featured Experts: Alice Chen, PhD, Jason Doctor, PhD, Dana Goldman, PhD, Darius Lakdawalla, PhD, Barry Liden, JD, Karen Mulligan, PhD, Desi Peneva, MS, Charles E. Phelps, PhD
Issue Brief
Operational and Policy Considerations in the Effectuation of Medicare’s Maximum Fair Drug Prices for Part D
October 16, 2025
Featured Experts: John M. Coster, PhD, RPh
News
Reform of Federal Drug Discount Program Should Target Misaligned Incentives
September 29, 2025
Featured Experts: Ryan Long, Karen Mulligan, PhD
News
Former FDA Leaders Say New Policies Needed to Boost Medical Innovation
September 26, 2025
Featured Experts: Lowell Schiller, JD, Barry Liden, JD
News
Schaeffer Center White Paper Outlines FDA Reforms to Boost Pharmaceutical Innovation and Expand Access
September 11, 2025
Featured Experts: Lowell Schiller, JD, Barry Liden, JD
White Paper
A Blueprint for FDA: Recommendations to Improve Innovation and Access
September 11, 2025
Featured Experts: Lowell Schiller, JD, Barry Liden, JD
Journal Article
Measuring the Budget Impact of Nondiscriminatory Cost-Effectiveness
September 5, 2025
Featured Experts: Karen Mulligan, PhD, Drishti Baid, MPP, Maria-Alice Manetas, Darius Lakdawalla, PhD
Perspective
Should the Government Control Drug Prices? Yes… Wise Regulation Will Reform an Out-of-Control Industry
September 2, 2025
Featured Experts: Paul Ginsburg, PhD, Steve M. Lieberman, MPhil, MA
Journal Article
Long-Term Value of Lecanemab to Individuals and Families
August 28, 2025
Featured Experts: Bryan Tysinger, PhD, Hanke Heun-Johnson, PhD, Julie Zissimopoulos, PhD
News
Narrower Coverage of MS Drugs Tied to Higher Relapse Risk
August 1, 2025
Featured Experts: Geoffrey Joyce, PhD
News
Delinking PBM Compensation From Drug List Prices Could Unleash Major Savings
July 24, 2025
Featured Experts: Geoffrey Joyce, PhD
Evidence Base
A Value-Based Price for Anti-Obesity Medications
July 17, 2025
Featured Experts: Alison Sexton Ward, PhD, Dana Goldman, PhD
Journal Article
Proposal for a Value-Based Agreement to Reimburse Anti-Obesity Medicines in Traditional Medicare
July 11, 2025
Featured Experts: Alison Sexton Ward, PhD, Erin Trish, PhD, Dana Goldman, PhD, Darius Lakdawalla, PhD
Comment Letter
Comments to USTR on Foreign Nations Freeloading on American-Financed Innovation
June 27, 2025
Featured Experts: Dana Goldman, PhD, Darius Lakdawalla, PhD, Barry Liden, JD
News
Most Medicare Beneficiaries May Pay More for Drugs Under the IRA
June 19, 2025
Featured Experts: Erin Trish, PhD
White Paper
Shifting Cost-Sharing Burden to Beneficiaries in Medicare Part D
June 19, 2025
Featured Experts: Erin Trish, PhD